

cAMP-Dependent Protein Kinase Enhances Inositol 1,4,5-Trisphosphate-Induced Ca²⁺ Release in AR4-2J Cells

Yannik Regimbald-Dumas, Guillaume Arguin, Marc-Olivier Fregeau, and Gaétan Guillemette*

Department of Pharmacology, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, Quebec J1H5N4, Canada

Abstract In non-excitabile cells, the inositol 1,4,5-trisphosphate receptor (IP₃R), a ligand-gated Ca²⁺ channel, plays an important role in the control of intracellular Ca²⁺. There are three subtypes of IP₃R that are differentially distributed among cell types. AR4-2J cells express almost exclusively the IP₃R-2 subtype. The purpose of this study was to investigate the effect of cAMP-dependent protein kinase (PKA) on the activity of IP₃R-2 in AR4-2J cells. We showed that immunoprecipitated IP₃R-2 is a good substrate for PKA. Using a back-phosphorylation approach, we showed that endogenous PKA phosphorylates IP₃R-2 in intact AR4-2J cells. Pretreatment with PKA enhanced IP₃-induced Ca²⁺ release in permeabilized AR4-2J cells. Pretreatment with the cAMP generating agent's forskolin and vasoactive intestinal peptide (VIP) enhanced carbachol (Cch)-induced and epidermal growth factor (EGF)-induced Ca²⁺ responses in intact AR4-2J cells. Our results are consistent with an enhancing effect of PKA on IP₃R-2 activity. This conclusion supports the emerging concept of crosstalk between Ca²⁺ signaling and cAMP pathways and thus provides another way by which Ca²⁺ signals are finely encoded within non-excitabile cells. *J. Cell. Biochem.* 101: 609–618, 2007. © 2007 Wiley-Liss, Inc.

Key words: inositol 1,4,5-trisphosphate receptor; phosphorylation; protein kinase A; calcium

Stimulation of a wide variety of cells by hormones, neurotransmitters, or growth factors leads to the activation of phospholipase C (PLC) and triggers inositol 1,4,5-trisphosphate (IP₃)-mediated Ca²⁺ signaling via activation of IP₃ receptors (IP₃Rs) on the endoplasmic reticulum [Berridge, 1993; Joseph and Ryan, 1993; Yoshida and Imai, 1997]. Intracellular Ca²⁺ is a key second messenger involved in a vast array of cellular processes such as contraction, secretion, growth, and differentiation. Three specific isoforms of IP₃R, encoded by different genes, have been isolated, with each isoform exhibiting unique tissue-specific expression patterns

[Furuichi et al., 1993; Maranto, 1994; Wojcikiewicz, 1995; Perez et al., 1997; Holtzclaw et al., 2002]. Co-immunoprecipitation studies have revealed that IP₃R isoforms can assemble as homotetramers (four identical isoforms) or as heterotetramers (two or three different isoforms within a tetramer) to constitute functional Ca²⁺ channels [Maeda et al., 1991; Monkawa et al., 1995]. Despite sharing considerable homology within their ligand-binding and channel domains, the amino acids sequence of each IP₃R isoform are least conserved in their regulatory domains. Ca²⁺ release through the IP₃R is markedly influenced by many factors such as Ca²⁺ itself, proteins, adenine nucleotides, and phosphorylation [Patterson et al., 2004]. These features are thought to be the major determinants of the rich diversity of Ca²⁺ signaling events observed in cells.

An emerging body of evidences, suggests that specific regulatory control over Ca²⁺ signaling pathways can be achieved by the simultaneous activation of additional signaling pathways, in particular those that elevate cAMP [Volpe and Alderson-Lang, 1990; Hajnoczky et al., 1993; Bruce et al., 2003]. Several studies have shown

Grant sponsor: Canadian Institutes of Health Research; Grant sponsor: Heart and Stroke Foundation of Quebec.

*Correspondence to: Gaétan Guillemette, Department of Pharmacology, Faculty of Medicine and Health Sciences, University of Sherbrooke, 3001 12th Avenue North, Sherbrooke, Quebec J1H5N4, Canada.

E-mail: gaetan.guillemette@usherbrooke.ca

Received 6 September 2006; Accepted 1 November 2006

DOI 10.1002/jcb.21221

© 2007 Wiley-Liss, Inc.

an important regulatory effect of cAMP-dependent protein kinase (PKA) on the activity of IP₃R-1 [DeSouza et al., 2002; Tang et al., 2003; Soulsby et al., 2004; Tu et al., 2004; Wagner et al., 2004]. Although these recent studies suggest that PKA increases the Ca²⁺ release sensitivity of IP₃R-1, little is known about the effect of PKA on IP₃R-2 and IP₃R-3.

The purpose of the present study was therefore to investigate the phosphoregulation of IP₃R-2 by PKA in AR4-2J cells, a pancreatic acinar cell line which expresses predominantly (86%) the IP₃R-2 isoform [Wojcikiewicz, 1995]. Our results demonstrate that IP₃R-2 is efficiently phosphorylated by exogenous and endogenous PKA. Pretreatment of AR4-2J cells with PKA or with cAMP generating agents enhanced IP₃-induced Ca²⁺ release and Cch- or EGF-induced Ca²⁺ responses. These results are consistent with a potentiating effect of PKA on IP₃R-2 activity.

MATERIALS AND METHODS

Materials

Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and penicillin-streptomycin-glutamine were from Gibco Life Technologies (Gaithersburg, MD). [γ -³²P]ATP was from Perkin Elmer (Boston, MA). IP₃ was from Alexis Biochemicals (San Diego, CA). Anti-IP₃R-2 antibody was obtained by immunizing New Zealand rabbits with the C-terminus of IP₃R-2 coupled to keyhole limpet hemocyanin [Poitras et al., 2000]. Protein AG-agarose was from Santa Cruz Technology (Santa Cruz, CA). Vasoactive intestinal peptide (VIP), forskolin, ATP, bovine serum albumin (BSA), creatine phosphokinase, phosphocreatine, poly-L-lysine hydrobromide, saponin, and thapsigargin were from Sigma-Aldrich (Oakville, ON). The catalytic subunit of cAMP-dependent protein kinase was from Promega (Madison, WI). Carbachol (CCh), fura-2 (free acid), fura-2/AM, phosphatases inhibitors cocktail set II, and okadaic acid were from Calbiochem (San Diego, CA). Proteases inhibitors cocktail (CompleteTM) was from Roche Molecular Biochemicals (Laval, QC).

Cell Culture

AR4-2J cells (American Type Culture Collection, Manassas, VA) were cultured at 37°C in a

humidified atmosphere of 5% CO₂ in DMEM medium containing L-glutamine (2 mM), FBS (15%, v/v), penicillin (100 U/ml), and streptomycin (100 µg/ml).

In Vitro Phosphorylation of IP₃R-2

AR4-2J cells (2×10^7 cells/ml) were solubilized for 1 h at 4°C, under gentle agitation, in lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100] supplemented with the proteases inhibitors cocktail CompleteTM (1×). The solubilized material was centrifuged at 30,000g for 30 min and the supernatant was immunoprecipitated for 16 h, at 4°C, under gentle agitation, with anti-IP₃R-2 antibody and 50 µl of protein AG-agarose beads. The immunoprecipitated IP₃R-2s were phosphorylated for different time periods at 30°C in phosphorylation buffer [40 mM Tris-HCl (pH 7.4), 20 mM MgCl₂] containing 10 µCi of [γ -³²P]ATP, 200 µM non-radioactive ATP, and the catalytic subunit of PKA (100–400 U/ml) in a final volume of 50 µl. The reaction was stopped by adding 1 ml of ice-cold phosphorylation buffer containing 1 mM ATP. Immune complexes were then precipitated by centrifugation for 1 min at 15,000g, washed twice with 1 ml of phosphorylation buffer containing 1 mM ATP, and resuspended in Laemmli buffer [Laemmli, 1970] for 10 min at 95°C. Samples were loaded onto a 4% SDS-PAGE gel that was run at 20 mA for 120 min. Gels were vacuum dried for 1 h at 80°C, and exposed for 24 h on a BioMax MR film with an intensifying screen. In some experiments, IP₃R subtypes were identified by immunoblotting with our anti-IP₃R-2 antibody or with the anti-IP₃R-1 antibody obtained from Affinity Bioreagents (Golden, CO). IP₃R subtypes were also identified by partial sequencing using a MALDI-TOF mass spectrometry approach after in-gel trypsin digestion. MALDI-MS mass spectra were recorded on a TofSpec 2E (Waters/Micromass Corporation, Manchester, England) using the delayed extraction and reflector mode. Acceleration and pulse voltages were set at 20,000 and 2,300 V, respectively, and the low-mass gate was 500. Peptide mass searches were performed with the Protein Prospector search engine (<http://prospector.ucsf.edu>) and the MASCOT algorithm (<http://www.matrixscience.com>). The latest versions of the NCBI and Swiss-Prot protein databases were used.

Back-Phosphorylation of IP₃R-2

AR4-2J cells were stimulated with 10 μ M forskolin in HBSS buffer [15 mM HEPES (pH 7.4), 140 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 10 mM dextrose, 1.8 mM CaCl₂, 0.1% (w/v) BSA]. Cells were then solubilized in 1 ml of ice-cold lysis buffer supplemented with 100 nM okadaic acid, (1 \times) phosphatases inhibitors cocktail set II, and (1 \times) proteases inhibitors cocktail CompleteTM. IP₃R-2 was then immunoprecipitated and phosphorylated in vitro as described above. In the back-phosphorylation procedure, it must be understood that an important in vivo phosphorylation of IP₃R-2 in treated AR4-2J cells will markedly diminish the level of incorporation of ³²Pi in the in vitro phosphorylation assay.

Dynamic Video Imaging of Cytosolic Ca²⁺

Fluorescence from fura 2-loaded cells was monitored as previously described [Auger-Messier et al., 2003]. Briefly, AR4-2J cells grown on glass coverslips were washed twice with HBSS buffer and loaded with 0.15 μ M fura-2/AM in HBSS buffer for 20 min at room temperature in the dark. After a de-esterification step (incubation in fresh HBSS for 20 min at room temperature) the coverslips were inserted into a circular open-bottom chamber and mounted on the stage of a Zeiss Axiovert microscope fitted with an Attofluor Digital Imaging and Photometry System (Attofluor, Inc., Rockville, MD). The system allows simultaneous data acquisition from up to 99 user-defined variably sized regions of interest (or cells) per field of view. As shown in the manuscript, among these single cells, some may not respond, some may show Ca²⁺ oscillations, and some may produce a single Ca²⁺ transient. Very interestingly, the same Attofluor system can calculate the average response of all the cells on the field. The average response is the mean fluorescence value calculated from individual fluorescence values obtained for all the selected cells in the field, at any time point. Average responses usually show Ca²⁺ transients of different intensities because all the cells start their response at about the same time but later on, oscillating cells usually lose their synchrony. In our study we have used the single cell application and also the average response application of the Attofluor system. Fluorescence from isolated fura-2-loaded cells was

monitored by videomicroscopy using alternative excitatory wavelengths of 334 and 380 nm and recording emitted fluorescence at 510 nm. All experiments were done at room temperature and the data are expressed as intracellular free Ca²⁺ concentration (nM) calculated from 334:380 fluorescence ratio according to Grynkiewicz et al. [1985].

IP₃-Induced Ca²⁺ Release

AR4-2J cells (5×10^7 cells) were permeabilized in 2 ml of cytosol-like buffer [20 mM Tris-HCl (pH 7.4), 10 mM NaCl, 110 mM KCl, 5 mM KH₂PO₄, and 2 mM MgCl₂] supplemented with 50 μ g/ml saponin, 0.5 μ M fura-2 acid, 20 Units creatine kinase, and 20 mM phosphocreatine. Fura-2 fluorescence was monitored at 37°C with a Hitachi F-2000 spectrofluorometer (Hitachi Scientific Instruments, Inc., Hialeah, FL) with alternative excitation wavelengths of 340 and 380 nm and with emission wavelength of 510 nm. The amount of Ca²⁺ released by IP₃ was calculated according to the fluorescent signal obtained with an exogenously added Ca²⁺ standard (4 nmol CaCl₂). At the end of each recording, maximal fluorescence ratio (R_{max}) and minimal fluorescence ratio (R_{min}) were determined by adding successively 2 mM Ca²⁺ and 10 mM EGTA to the cells suspension. When needed, free Ca²⁺ concentration was calculated according to Grynkiewicz et al. [1985].

Data Analysis

Results are presented as the mean \pm standard deviation. When needed, data were analyzed by a Student's *t*-test. *P* values of <0.05 were considered statistically significant (*).

RESULTS

Phosphorylation of IP₃R-2

Previous studies have shown that AR4-2J cells express predominantly (86%) the IP₃R-2, making them a convenient model to study the pharmacological and functional properties of this specific IP₃R subtype [Wojcikiewicz, 1995]. IP₃R from AR4-2J cells were solubilized in lysis buffer, immunoprecipitated with anti-IP₃R-2 antibody, and phosphorylated in vitro as described in Materials and Methods section. Figure 1A shows that within a period of 30 min, efficient phosphorylation of IP₃R-2 was obtained with a relatively high concentration of PKA (400 U/ml). The bands migrating with




Fig. 1. Phosphorylation of IP₃R-2. IP₃R-2 from 2×10^7 AR4-2J cells was solubilized in lysis buffer, immunoprecipitated with anti-IP₃R-2 antibody, phosphorylated in vitro with the catalytic subunit of PKA, and analyzed by 4% SDS-PAGE and autoradiography, as described in Materials and Methods section. In **panel A**, IP₃R-2 was phosphorylated in vitro for 30 min with increasing amounts of PKA. In **panel B**, IP₃R-2 was phosphorylated in vitro with exogenous PKA (400 U/ml), for different time periods. These results are representative of three independent experiments. In **panel C**, AR4-2J cells were pre-treated with 10 μ M forskolin before solubilization in lysis buffer. IP₃R-2 was then immunoprecipitated and phosphorylated in vitro. Proteins were then resolved on a 4% SDS-PAGE gel and autoradiographed (**upper panel**). The **lower panel** shows the Coomassie blue staining of the same bands. The results shown in panel C are representative of four independent experiments.

Mrs 260 and 230 kDa were identified as IP₃R-1 and IP₃R-2, respectively, by partial sequencing using a MALDI-TOF mass spectrometry approach and by immunoblotting (data not shown). Figure 1B shows that in vitro phosphorylation of IP₃R-2 (with 400 U/ml exogenous PKA) was detectable within 5 min and reached a high level by 60 min. These results clearly indicate that exogenous PKA can phosphorylate IP₃R-2. Next, we used a back-phosphorylation procedure to determine whether endogenous PKA can phosphorylate IP₃R-2. Intact AR4-2J cells were first stimulated for 1 min with forskolin, an indirect activator of PKA. IP₃R-2 was then solubilized, immunoprecipitated, and phosphorylated in vitro with exogenous PKA and [γ -³²P]ATP. Figure 1C shows a robust PKA-mediated back-phosphorylation of IP₃R-2 that had been immunoprecipitated from untreated AR4-2J cells, indicating that very little phos-




Fig. 2. PKA increases IP₃-induced Ca²⁺ release in permeabilized AR4-2J cells. AR4-2J cells (5×10^7) were permeabilized with 100 μ g/ml saponin and pre-treated for 2 min with vehicle (**panel A**) or 400 U/ml PKA (**panel B**) in a cytosol-like medium containing 0.5 μ M fura-2 acid. Ca²⁺ was then partially released with 0.1 μ M IP₃ (I). The amount of Ca²⁺ released by IP₃ was calibrated by adding 4 nmoles of exogenous Ca²⁺ (Ca²⁺). These typical traces are representative of at least three independent experiments. **Panel C** shows the dose-response curves (under the same experimental conditions) for IP₃-induced Ca²⁺ release from permeabilized untreated (open circle) or PKA-treated (filled circle) AR4-2J cells. **Panel D** shows the total content of the Ca²⁺ pool released with 2 μ M ionomycin from permeabilized AR4-2J cells pre-treated with vehicle (empty bar) or with PKA (filled bar). The results shown in panels C and D are representative of five independent experiments.

phorylation occurs under basal conditions (Fig. 2C, control). After 1 min pre-treatment with forskolin (Fig. 2C, Forsk.), back-phosphorylation with PKA decreased significantly, suggesting that forskolin increases IP₃R-2 phosphorylation by PKA in intact AR4-2J cells.

PKA Enhances IP₃-Induced Ca²⁺ Release in AR4-2J Cells

We used a direct IP₃-induced Ca²⁺ release assay that measures ambient Ca²⁺ concentrations by fura-2 fluorescence to study the functional consequences of PKA phosphorylation. Figure 2A shows a typical experiment where 0.1 μ M IP₃ released 4.5 nmol of Ca²⁺ from permeabilized AR4-2J cells. The amount of Ca²⁺ released was calibrated by the exogenous addition of 4 nmol CaCl₂. In PKA-treated permeabilized cells (Fig. 2B), 0.1 μ M IP₃ released 6.8 nmol of Ca²⁺, an amount which is

larger than in untreated cells. These results indicate that PKA enhances IP₃-induced Ca²⁺ release in AR4-2J cells. The dose-response curve for IP₃-induced Ca²⁺ release from PKA-treated cells showed a leftward shift (EC₅₀ of 58 ± 6 nM, average and standard deviation of three experiments) compared to the dose-response curve for IP₃-induced Ca²⁺ release from control cells (EC₅₀ of 92 ± 10 nM; Fig. 2C). In paired experiments (similar to those shown in panels 2A and B), there was no significant difference in the amount of Ca²⁺ released by untreated and PKA-treated permeabilized cells at a maximal dose of IP₃ (Fig. 2C). Treatment with 2 μM ionomycin (Fig. 2D) or with 2 μM thapsigargin (data not shown) revealed that the IP₃-releasable Ca²⁺ pool of PKA-treated cells was similar to that of vehicle-treated cells. These results suggest that PKA enhances IP₃-induced Ca²⁺ release by increasing the apparent affinity of IP₃Rs.

Forskolin Enhances CCH-Induced Ca²⁺ Responses in Intact AR4-2J Cells

To determine the functional consequence of PKA phosphorylation, we also evaluated the cytosolic Ca²⁺ concentration in intact AR4-2J cells loaded with fura-2/AM. When cells were incubated in a medium prepared without Ca²⁺ (0.5 mM EGTA), a low dose of the Ca²⁺-mobilizing agonist Cch (1 μM) produced a Ca²⁺ increase with a peak amplitude of 95 ± 13 nM (Fig. 3A). After a 3 min pre-treatment with forskolin, 1 μM Cch produced a much stronger Ca²⁺ increase with a peak amplitude of 135 ± 11 nM (Fig. 3B). Because these experiments were done in the absence of extracellular Ca²⁺, it is likely that the Ca²⁺ responses produced by Cch were due to IP₃-induced Ca²⁺ release from intracellular stores. These results, which were obtained with intact cells, are consistent with a potentiating effect of PKA on IP₃-induced Ca²⁺ release.

Our dynamic video imaging system allows single cell responses to be recorded. When the Ca²⁺ movements were investigated at the single cell level, two types of responses were observed. At a low dose of Cch (1 μM) 23 ± 6% of cells did not show any change in their Ca²⁺ concentration whereas 27 ± 7% of cells responded with a single Ca²⁺ transient of high amplitude (Fig. 4A) and 50 ± 6% of cells began rapid Ca²⁺ oscillations that lasted for about 3 min (Fig. 4B). At higher doses of Cch, the proportion of cells




Fig. 3. Forskolin increases Cch-induced Ca²⁺ responses in intact AR4-2J cells. AR4-2J cells were loaded with fura-2/AM and bathed in a Ca²⁺-free extracellular medium. Cells were imaged using a Zeiss Axiovert microscope (40× oil immersion objective) coupled to an Attofluor imaging system. Representative recordings of intracellular Ca²⁺ levels before and after the addition of 1 μM Cch to cells pre-treated with vehicle (**panel A**, average response of 84 cells), or with forskolin (**panel B**, average response of 61 cells). **Panel C** shows the average Ca²⁺ responses (means ± SD, *P < 0.05) obtained from three independent experiments, for cells pretreated with vehicle (empty bar, average response of 244 cells) or with forskolin (filled bar, average response of 195 cells) and stimulated with 1 μM Cch.

that did not respond decreased and the proportion of cells that responded with a single transient increased (Fig. 4C). These results illustrate the graded responses obtained with stimuli of increasing intensity, going from no significant response to an oscillatory pattern and to a single transient of high amplitude. A similarly enhanced response to 1 μM Cch was observed after a pretreatment of AR4-2J cells with 10 μM forskolin. As demonstrated by the average response of a cell population stimulated with Cch (Fig. 3), analysis of single cell responses revealed that forskolin enhances Cch-induced Ca²⁺ responses (Fig. 4D). Indeed, after a pretreatment with forskolin, only 8 ± 5% of cells did not show any change in their Ca²⁺ concentration whereas 36 ± 3% of cells began rapid Ca²⁺ oscillations that lasted for about 3 min, and 56 ± 4% of cells responded with a single Ca²⁺ transient of high amplitude. These results are consistent with a potentiating effect of PKA on IP₃-induced Ca²⁺ release.

Forskolin Enhances EGF-Induced Ca²⁺ Responses In AR4-2J Cells

Epidermal growth factor (EGF) activates a receptor-tyrosine kinase that in turn activates




Fig. 4. Cch-induced Ca^{2+} signaling in single AR4-2J cells loaded with fura-2/AM, in the absence of extracellular Ca^{2+} . **A:** It shows serial images depicting a typical Ca^{2+} transient (according to the pseudocolor scale) within a cell stimulated with 1 μM Cch. The trace below shows the full time Ca^{2+} response of the same cell. **B:** It shows serial images depicting typical Ca^{2+} oscillations within a cell stimulated with 1 μM Cch. The trace below shows the full time Ca^{2+} response of the same cell. **C:** It shows the

phospholipase $\text{C}\beta$ and produces small amounts of IP_3 . In a Ca^{2+} -free medium (0.5 mM EGTA), 200 ng/ml EGF caused a slow, weak Ca^{2+} increase with a peak amplitude of 45 ± 9 nM (Fig. 5A). After a 2 min pre-treatment with 10 μM forskolin, EGF produced a stronger Ca^{2+} increase with a peak amplitude of 65 ± 6 nM (Fig. 5B). These results demonstrate that the potentiating effect of forskolin is due to the regulation of a component common to the distinct Ca^{2+} signaling pathways used by Cch and EGF. These results are consistent with a potentiating effect of PKA on IP_3 -induced Ca^{2+} release.

Vip Enhances CCH-Induced Ca^{2+} Responses in AR4-2J Cells

On AR4-2J cells, VIP activates a G-protein-coupled receptor that couples to G_s , elevates cAMP levels, and activates PKA. After a 3 min pretreatment with 1 μM VIP, the Ca^{2+} response produced by 1 μM Cch (Fig. 6A, filled circle) showed a peak amplitude of 106 ± 10 nM (Fig. 6B) a value significantly higher than that

proportions of cells responding with Ca^{2+} oscillations (Osc), Ca^{2+} transient (Trans) or not responding (NR) to increasing doses of Cch. **D:** It shows the proportions of cells responding with Ca^{2+} oscillations (Osc), Ca^{2+} transient (Trans), or not responding (NR) to 1 μM Cch after a 3 min pre-treatment with vehicle (empty bars) or with forskolin (filled bars). These results are representative of at least three independent experiments.

observed with untreated cells (Fig. 6A, empty circle) 67 ± 13 nM (Fig. 6B). When these results were analyzed at the single cell level, VIP clearly enhanced Cch-induced Ca^{2+} responses. The proportion of cells that did not respond to Cch (1 μM) went from $33 \pm 7\%$ for untreated cells to $9 \pm 3\%$ for VIP-pretreated cells, the proportion of cells that responded with oscillations went from $49 \pm 7\%$ for untreated cells to $37 \pm 2\%$ for VIP-pretreated cells and the proportion of cells that showed a single transient went from $18 \pm 4\%$ for untreated cells to $55 \pm 4\%$ for VIP-pretreated cells. These results demonstrate that the potentiating effect of PKA activation could also be obtained by the activation G-protein-coupled receptor that couples to G_s . These results are consistent with a potentiating effect of PKA on IP_3 -induced Ca^{2+} release.

VIP Enhances Overall CCH-Induced Ca^{2+} Responses in AR4-2J Cells

We also evaluated the functional impact of a treatment with VIP on the overall Ca^{2+}




Fig. 5. Forskolin increases EGF-induced Ca²⁺ response in intact AR4-2J cells. AR4-2J cells were loaded with fura-2/AM, bathed in a Ca²⁺-free extracellular medium, and imaged with the Atof fluor system. Representative average Ca²⁺ response, before and after the addition of 200 ng/ml EGF to cells pre-treated with vehicle (**panel A**, average response of 82 cells), or with forskolin (**panel B**, average response of 77 cells). **Panel C** shows data (means ± SD, *P < 0.01) obtained from three independent experiments, for cells pretreated for 3 min with vehicle (empty bar, average response of 315 cells) or with 10 μM forskolin (filled bar, average response of 354 cells) and stimulated with 200 ng/ml EGF.

response of intact AR4-2J cells incubated in a medium containing a normal (1.8 mM) Ca²⁺ concentration. Under these conditions, agonist-induced intracellular Ca²⁺ movements are due to Ca²⁺ release from the intracellular stores and also to Ca²⁺ entry from the extracellular medium. Figure 7A shows a typical trace where, in the presence of extracellular Ca²⁺, cells responded to 1 μM Cch by barely detectable baseline Ca²⁺ oscillations of low amplitude. The addition of 1 μM VIP to these cells induced strong oscillations of high amplitude. Under the same conditions few cells responded to 1 μM Cch by producing oscillations of high amplitude (Fig. 7B). The addition of 1 μM VIP to these cells accelerated the oscillatory pattern to generate a large single Ca²⁺ transient. It is interesting to note that the rapidity of the response to VIP (less than 1 min) is consistent with the rapidity of IP₃R-2 phosphorylation within intact AR4-2J cells (Fig. 1C). All together these results demonstrated that the activation of a Gs-coupled receptor enhances Cch-induced Ca²⁺ response in AR4-2J cells. This effect could occur, at least in part, through a potentiating effect of PKA on IP₃-induced Ca²⁺ release.




Fig. 6. VIP increases Cch-induced Ca²⁺ response in intact AR4-2J cells. AR4-2J cells were loaded with fura-2/AM, bathed in a Ca²⁺-free extracellular medium, and imaged with the Atof fluor system. Representative recordings of intracellular Ca²⁺ levels before and after the addition of 1 μM Cch to cells pre-treated with vehicle (**panel A**, empty circle, average response of 49 cells), or with 1 μM VIP (**panel A**, filled circle, average response of 44 cells). **Panel B** shows data (means ± SD, *P < 0.05) obtained from three independent experiments, for cells pretreated for 3 min with vehicle (empty bar, average response of 138 cells) or with 1 μM VIP (filled bar, average response of 151 cells) and stimulated with 1 μM Cch. **Panel C** shows the proportions of cells responding with Ca²⁺ oscillations (Osc), Ca²⁺ transient (Trans), or not responding (NR) to 1 μM Cch after a 3 min pre-treatment with vehicle (empty bars) or with 1 μM VIP (filled bars). The results presented in panel C are representative of three independent experiments.

DISCUSSION

The regulatory domain of IP₃R-2 contains a putative phosphorylation site for PKA (R/K)(R/




Fig. 7. VIP potentiates the overall Cch-induced Ca^{2+} response of AR4-2J cells. AR4-2J cells were loaded with fura-2/AM, bathed in a normal Ca^{2+} medium (1.8 mM), and imaged with the Atof fluor system. Representative recordings of intracellular Ca^{2+} levels before and after the addition of $1 \mu\text{M}$ Cch followed by $1 \mu\text{M}$ VIP. The typical trace shown in **panel A** illustrates the response of a single cell that, upon VIP addition, goes from a barely

detectable Ca^{2+} elevation to a strong Ca^{2+} oscillatory pattern. The typical trace shown in **panel B** illustrates the response of another single cell that, upon VIP addition goes from a Ca^{2+} oscillatory pattern to a single Ca^{2+} transient of high amplitude. These results are representative of responses obtained with more than 100 cells, in three independent experiments.

K)X(S/T) at serine 1,687, suggesting that it could be a substrate for PKA. In the present study, we used a direct in vitro phosphorylation assay to demonstrate that PKA dose-dependently and time-dependently phosphorylates $\text{IP}_3\text{R-2}$. These results support and extend those of a previous study reporting that $\text{IP}_3\text{R-2}$ was a relatively poor substrate for PKA [Wojcikiewicz and Luo, 1998]. Using an indirect back-phosphorylation approach, we further showed that $\text{IP}_3\text{R-2}$ is phosphorylated by endogenous PKA in AR4-2J cells. Several studies already demonstrated that IP_3Rs are substrates for PKA but these studies were done with tissues expressing almost exclusively the $\text{IP}_3\text{R-1}$ subtype or various proportions of the different subtypes of IP_3Rs [Ferris et al., 1991; Hajnoczky et al., 1993; Giovannucci et al., 2000; Wagner et al., 2003; Soulsby and Wojcikiewicz, 2005]. Our results clearly demonstrated that $\text{IP}_3\text{R-2}$ is a good substrate for PKA.

There is still no clear consensus on the functional consequences of IP_3R subtype specific phosphorylation by PKA. Several studies concluded that PKA decreases IP_3 -induced Ca^{2+} release. In rat brain microsomes, a tissue containing almost exclusively $\text{IP}_3\text{R-1}$, PKA decreased IP_3 -induced Ca^{2+} release [Supattapone et al., 1988]. In canine tracheal smooth muscle cells (undefined composition of IP_3R -channel), cAMP elevating agents diminished Cch-induced intracellular Ca^{2+} mobilization [Yang et al., 1996]. In mouse pancreatic acinar cells containing a mixture of $\text{IP}_3\text{R-1}$, $\text{IP}_3\text{R-2}$, and $\text{IP}_3\text{R-3}$, PKA reduced the amplitude and frequency of Cch-induced intracellular Ca^{2+} oscil-

lations [Giovannucci et al., 2000] and markedly slowed the kinetics of cholecystokinin-evoked Ca^{2+} oscillations [Straub et al., 2002].

On the contrary, several studies concluded that PKA increases IP_3 -induced Ca^{2+} release. In rat hepatocytes (undefined IP_3R /channel composition), [^3H] IP_3 -binding affinity and IP_3 -induced Ca^{2+} mobilization were enhanced by PKA [Hajnoczky et al., 1993; Joseph and Ryan, 1993]. With purified $\text{IP}_3\text{R-1}$ reconstituted into lipid vesicles, both the rate and extent of $^{45}\text{Ca}^{2+}$ influx into proteoliposomes increased by 20% after incubation with the catalytic subunit of PKA [Nakade et al., 1994]. In DT-40 cells expressing exclusively the $\text{IP}_3\text{R-1}$ subtype, it was unambiguously shown that PKA markedly enhances IP_3 -induced Ca^{2+} release [Wagner et al., 2003, 2004]. The sensitivity of recombinant $\text{IP}_3\text{R-1}$ reconstituted into planar lipid bilayers was increased by fourfold after phosphorylation with PKA [Tang et al., 2003]. In permeabilized SH-SY5Y cells (which contain almost exclusively $\text{IP}_3\text{R-1}$), PKA produced a biphasic effect (stimulatory at low concentrations and inhibitory at high concentrations) on IP_3 -induced Ca^{2+} release [Dyer et al., 2003]. For many reasons, including cell type-specific expression of IP_3R subtypes and of accessory proteins or factors that can influence the Ca^{2+} -handling machinery, it has been difficult to functionally assess the effect of PKA phosphorylation of IP_3R . Although the most recent studies show that PKA increases the Ca^{2+} release sensitivity of $\text{IP}_3\text{R-1}$, little is known about the effect of PKA on $\text{IP}_3\text{R-2}$ and $\text{IP}_3\text{R-3}$.

Here we showed that PKA enhances IP₃-induced Ca²⁺ release in permeabilized AR4-2J cells. This is a straightforward assay that evaluates the direct effect of IP₃ on its receptor/channel. Because PKA did not modify the content of the thapsigargin- and ionomycin-sensitive Ca²⁺ pool, the enhanced Ca²⁺ release must be due to the enhanced activity of IP₃R. Dose-response curves for IP₃-induced Ca²⁺ release revealed that PKA increases the apparent affinity of IP₃R in AR4-2J cells. It must be noted that AR4-2J cells express a very low level of IP₃R-1 that is also a substrate for PKA (as shown in Fig. 1). Recent evidences suggest that the activity of IP₃R-1 is potentiated by PKA [Nakade et al., 1994; Tang et al., 2003; Wagner et al., 2003, 2004]. However, AR4-2J cells express predominantly the IP₃R-2, and we assume that the Ca²⁺ responses within these cells are mostly due to the activity of IP₃R-2. Therefore, our results suggest that PKA enhances the activity of IP₃R-2.

It was previously shown that VIP and forskolin activate the adenylyl cyclase and PKA in AR4-2J cells [Simeone et al., 1995; Wojcikiewicz and Luo, 1998]. Using intact AR4-2J cells incubated in a Ca²⁺-free medium, we showed that a pretreatment with forskolin (an indirect activator of PKA) or with VIP (a cAMP elevating agonist) enhanced Cch- and EGF-induced Ca²⁺ elevations. Experiments performed at the single cell level also showed that forskolin and VIP enhance Cch-induced Ca²⁺ responses in AR4-2J cells. Lastly, using intact AR4-2J cells bathing in a normal Ca²⁺-containing medium, we showed that VIP unequivocally boosted the Ca²⁺ response induced by Cch. Notwithstanding the fact that within intact cells, PKA may have numerous other substrates, these results are consistent with an enhancing effect of PKA on IP₃R-2 activity. The weight of evidences presented here suggests that PKA phosphorylates IP₃R-2 and potentiates Cch-induced Ca²⁺ signaling in AR4-2J cells. These results further support the emerging concept of crosstalk between Ca²⁺ signaling and cAMP pathways and thus provide another way by which Ca²⁺ signals are finely encoded within cells.

ACKNOWLEDGMENTS

This work was supported by the Canadian Institutes of Health Research and from the

Heart and Stroke Foundation of Quebec. G.A. is a recipient of the National Sciences and Engineering Research Council of Canada studentship award. This work is part of the Ph.D. thesis of Y. R-D.

REFERENCES

- Auger-Messier M, Clement M, Lanctot PM, Leclerc PC, Leduc R, Escher E, Guillemette G. 2003. The constitutively active N111G-AT1 receptor for angiotensin II maintains a high affinity conformation despite being uncoupled from its cognate G protein Gq/11a. *Endocrinology* 144:5277–5284.
- Berridge MJ. 1993. Cell signalling. A tale of two messengers. *Nature* 365:388–389.
- Bruce JI, Straub SV, Yule DI. 2003. Crosstalk between cAMP and Ca²⁺ signaling in non-excitabile cells. *Cell Calcium* 34:431–444.
- DeSouza N, Reiken S, Ondrias K, Yang YM, Matkovich S, Marks AR. 2002. Protein kinase A and two phosphatases are components of the inositol 1,4,5-trisphosphate receptor macromolecular signaling complex. *J Biol Chem* 277:39397–39400.
- Dyer JL, Mobasheri H, Lea EJ, Dawson AP, Michelangeli F. 2003. Differential effect of PKA on the Ca²⁺ release kinetics of the type I and III InsP₃ receptors. *Biochem Biophys Res Commun* 302:121–126.
- Ferris CD, Cameron AM, Bredt DS, Hagan RL, Snyder SH. 1991. Inositol 1,4,5-trisphosphate receptor is phosphorylated by cyclic AMP-dependent protein kinase at serines 1755 and 1589. *Biochem Biophys Res Commun* 175:192–198.
- Furuichi T, Simon-Chazottes D, Fujino I, Yamada N, Hasegawa M, Miyawaki A, Yoshikawa S, Guenet JL, Mikoshiba K. 1993. Widespread expression of inositol 1,4,5-trisphosphate receptor type 1 gene (Insp3r1) in the mouse central nervous system. *Recept Channels* 1:11–24.
- Giovannucci DR, Groblewski GE, Sneyd J, Yule DI. 2000. Targeted phosphorylation of inositol 1,4,5-trisphosphate receptors selectively inhibits localized Ca²⁺ release and shapes oscillatory Ca²⁺ signals. *J Biol Chem* 275:33704–33711.
- Grynkiewicz G, Poenie M, Tsien RY. 1985. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. *J Biol Chem* 260:3440–3450.
- Hajnoczky G, Gao E, Nomura T, Hoek JB, Thomas AP. 1993. Multiple mechanisms by which protein kinase A potentiates inositol 1,4,5-trisphosphate-induced Ca²⁺ mobilization in permeabilized hepatocytes. *Biochem J* 293(Pt 2):413–422.
- Holtzclaw LA, Pandhit S, Bare DJ, Mignery GA, Russell JT. 2002. Astrocytes in adult rat brain express type 2 inositol 1,4,5-trisphosphate receptors. *Glia* 39:69–84.
- Joseph SK, Ryan SV. 1993. Phosphorylation of the inositol trisphosphate receptor in isolated rat hepatocytes. *J Biol Chem* 268:23059–23065.
- Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680–685.
- Maeda N, Kawasaki T, Nakade S, Yokota N, Taguchi T, Kasai M, Mikoshiba K. 1991. Structural and functional characterization of inositol 1,4,5-trisphosphate receptor

- channel from mouse cerebellum. *J Biol Chem* 266:1109–1116.
- Maranto AR. 1994. Primary structure, ligand binding, and localization of the human type 3 inositol 1,4,5-trisphosphate receptor expressed in intestinal epithelium. *J Biol Chem* 269:1222–1230.
- Monkawa T, Miyawaki A, Sugiyama T, Yoneshima H, Yamamoto-Hino M, Furuichi T, Saruta T, Hasegawa M, Mikoshiba K. 1995. Heterotetrameric complex formation of inositol 1,4,5-trisphosphate receptor subunits. *J Biol Chem* 270:14700–14704.
- Nakade S, Rhee SK, Hamanaka H, Mikoshiba K. 1994. Cyclic AMP-dependent phosphorylation of an immunopurified homotetrameric inositol 1,4,5-trisphosphate receptor (type I) increases Ca^{2+} flux in reconstituted lipid vesicles. *J Biol Chem* 269:6735–6742.
- Patterson RL, Boehning D, Snyder SH. 2004. Inositol 1,4,5-trisphosphate receptors as signal integrators. *Annu Rev Biochem* 73:437–465.
- Perez PJ, Ramos-Franco J, Fill M, Mignery GA. 1997. Identification and functional reconstitution of the type 2 inositol 1,4,5-trisphosphate receptor from ventricular cardiac myocytes. *J Biol Chem* 272:23961–23969.
- Poitras M, Poirier SN, Laflamme K, Simoneau M, Escher E, Guillemette G. 2000. Different populations of inositol 1,4,5-trisphosphate receptors expressed in the bovine adrenal cortex. *Recept Channels* 7:41–52.
- Simeone DM, Yule DI, Logston CD, Williams JA. 1995. Ca^{2+} signaling through secretagogue and growth factor receptors on pancreatic AR4-2J cells. *Regul Pept* 55(2):197–206.
- Soulsby MD, Wojcikiewicz RJ. 2005. The type III inositol 1,4,5-trisphosphate receptor is phosphorylated by cAMP-dependent protein kinase at three sites. *Biochem J* 392:493–497.
- Soulsby MD, Alzayady K, Xu Q, Wojcikiewicz RJ. 2004. The contribution of serine residues 1588 and 1755 to phosphorylation of the type I inositol 1,4,5-trisphosphate receptor by PKA and PKG. *FEBS Lett* 557:181–184.
- Straub SV, Giovannucci DR, Bruce JI, Yule DI. 2002. A role for phosphorylation of inositol 1,4,5-trisphosphate receptors in defining calcium signals induced by peptide agonists in pancreatic acinar cells. *J Biol Chem* 277:31949–31956.
- Supattapone S, Danoff SK, Theibert A, Joseph SK, Steiner J, Snyder SH. 1988. Cyclic AMP-dependent phosphorylation of a brain inositol trisphosphate receptor decreases its release of calcium. *Proc Natl Acad Sci USA* 85:8747–8750.
- Tang TS, Tu H, Wang Z, Bezprozvanny I. 2003. Modulation of type 1 inositol (1,4,5)-trisphosphate receptor function by protein kinase a and protein phosphatase 1alpha. *J Neurosci* 23:403–415.
- Tu H, Tang TS, Wang Z, Bezprozvanny I. 2004. Association of type 1 inositol 1,4,5-trisphosphate receptor with AKAP9 (Yotiao) and protein kinase A. *J Biol Chem* 279:19375–19382.
- Volpe P, Alderson-Lang BH. 1990. Regulation of inositol 1,4,5-trisphosphate-induced Ca^{2+} release. II. Effect of cAMP-dependent protein kinase. *Am J Physiol* 258:C1086–91.
- Wagner LE II, Li WH, Yule DI. 2003. Phosphorylation of type-1 inositol 1,4,5-trisphosphate receptors by cyclic nucleotide-dependent protein kinases: A mutational analysis of the functionally important sites in the S2+ and S2– splice variants. *J Biol Chem* 278:45811–45817.
- Wagner LE II, Li WH, Joseph SK, Yule DI. 2004. Functional consequences of phosphomimetic mutations at key cAMP-dependent protein kinase phosphorylation sites in the type 1 inositol 1,4,5-trisphosphate receptor. *J Biol Chem* 279:46242–46252.
- Wojcikiewicz RJ. 1995. Type I, II, and III inositol 1,4,5-trisphosphate receptors are unequally susceptible to down-regulation and are expressed in markedly different proportions in different cell types. *J Biol Chem* 270:11678–11683.
- Wojcikiewicz RJ, Luo SG. 1998. Phosphorylation of inositol 1,4,5-trisphosphate receptors by cAMP-dependent protein kinase. Type I, II, and III receptors are differentially susceptible to phosphorylation and are phosphorylated in intact cells. *J Biol Chem* 273:5670–5677.
- Yang CM, Hsu MC, Tsao HL, Chiu CT, Ong R, Hsieh JT, Fan LW. 1996. Effect of cAMP elevating agents on carbachol-induced phosphoinositide hydrolysis and calcium mobilization in cultured canine tracheal smooth muscle cells. *Cell Calcium* 19:243–254.
- Yoshida Y, Imai S. 1997. Structure and function of inositol 1,4,5-trisphosphate receptor. *Jpn J Pharmacol* 74:125–137.